A cementless, anatomic ceramic hip resurfacing device may be safe and effective, with a low all-cause revision rate at 8-year ...

The FDA approved belantamab mafodotin-blmf in combination with bortezomib and dexamethasone for the treatment of certain ...

The FDA declined to approve SYD-101, a low-dose atropine formulation that would have been the first pharmaceutical treatment ...

The FDA has approved once-daily oral Lynkuet for the treatment of moderate to severe hot flashes caused by menopause, ...

Academic medicine can be a rewarding path filled with opportunities for personal and professional growth, from teaching ...

Women who experience menopause at an earlier age and have a reduction in cardiac function are at increased risk for adverse ...

Topcon Healthcare launched IDHea Inc., a company focused on driving clinical research and oculomics to advance eye care, ...

Preliminary results presented here showed use of a custom-tailored AI platform may be a feasible option to address ...

The FDA approved revumenib for patients aged 1 year and older with relapsed or refractory acute myeloid leukemia with a ...

Among individuals with MS, the risk of serious infection was higher and the time to the first serious infection was shorter ...

Homelessness was linked to lower mortality rates and costs but longer stays and more discharges against medical advice for ...

Once-weekly semaglutide 2.4 mg conferred a greater reduction in major adverse cardiovascular events than placebo, regardless ...